ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > PMN penny stock again

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Oct 10, 2024 7:04pm

95 Views

Post# 36261892

RE:RE:RE:PMN penny stock again

Hafness wrote: I guess it is safe to say that there will be no movement till first clinical read outs. That is pretty far off. Couple of years. How do they stay on Nasdaq being below 5$ this long. Can't keep doing splits dissolving current ownership. Right?

If I remember correctly, we were here once before with the Nasdaq issue. The insiders stepped in and pumped it back up to $2 — the rinse-and-repeat scenario.

A good time to buy.

jmo
G1945V

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec